Reference : 1,2,4-Triazole-3-thione compounds with a 4-ethyl alkyl/aryl sulfide substituent are b...
Scientific journals : Article
Human health sciences : Pharmacy, pharmacology & toxicology
Life sciences : Biochemistry, biophysics & molecular biology
Life sciences : Microbiology
1,2,4-Triazole-3-thione compounds with a 4-ethyl alkyl/aryl sulfide substituent are broad-spectrum metallo-β-lactamase inhibitors with re-sensitization activity
Legru, Alice [> >]
Verdirosa, Federica [> >]
Hernandez, Jean-François [> >]
Tassone, Giusy [> >]
Sannio, Filomena [> >]
Benvenuti, Manuela [> >]
Conde, Pierre-Alexis [> >]
Bossis, Guillaume [> >]
Thomas, Caitlyn A. [> >]
Crowder, Michael W. [> >]
Dillenberger, Melissa [> >]
Becker, Katja [> >]
Pozzi, Cecilia [> >]
Mangani, Stefano [> >]
Docquier, Jean-Denis mailto [Université de Liège - ULiège > Département des sciences de la vie > Centre d'ingénierie des protéines >]
Gavara, Laurent [> >]
European Journal of Medicinal Chemistry
Yes (verified by ORBi)
[en] 1,2,4-Triazole-3-thione ; Bacterial resistance ; Metallo-β-Lactamase inhibitor ; Thioether ; β-lactam antibiotic
[en] Metallo-β-lactamases (MBLs) are important contributors of Gram-negative bacteria resistance to β-lactam antibiotics. MBLs are highly worrying because of their carbapenemase activity, their rapid spread in major human opportunistic pathogens while no clinically useful inhibitor is available yet. In this context, we are exploring the potential of compounds based on the 1,2,4-triazole-3-thione scaffold as an original ligand of the di-zinc active sites of MBLs, and diversely substituted at its positions 4 and 5. Here, we present a new series of compounds substituted at the 4-position by a thioether-containing alkyl chain with a carboxylic and/or an aryl group at its extremity. Several compounds showed broad-spectrum inhibition with Ki values in the μM to sub-μM range against VIM-type enzymes, NDM-1 and IMP-1. The presence of the sulfur and of the aryl group was important for the inhibitory activity and the binding mode of a few compounds in VIM-2 was revealed by X-ray crystallography. Importantly, in vitro antibacterial susceptibility assays showed that several inhibitors were able to potentiate the activity of meropenem on Klebsiella pneumoniae clinical isolates producing VIM-1 or VIM-4, with a potentiation effect of up to 16-fold. Finally, a selected compound was found to only moderately inhibit the di-zinc human glyoxalase II, and several showed no or only moderate toxicity toward several human cells, thus favourably completing a promising behaviour.

File(s) associated to this reference

Fulltext file(s):

Restricted access
99.pdfPublisher postprint2.92 MBRequest copy

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.